2gfy: Difference between revisions

New page: left|200px<br /><applet load="2gfy" size="450" color="white" frame="true" align="right" spinBox="true" caption="2gfy, resolution 2.85Å" /> '''Structure of E. coli...
 
No edit summary
Line 1: Line 1:
[[Image:2gfy.gif|left|200px]]<br /><applet load="2gfy" size="450" color="white" frame="true" align="right" spinBox="true"  
[[Image:2gfy.gif|left|200px]]<br /><applet load="2gfy" size="350" color="white" frame="true" align="right" spinBox="true"  
caption="2gfy, resolution 2.85&Aring;" />
caption="2gfy, resolution 2.85&Aring;" />
'''Structure of E. coli FabF(K335A) mutant with covalently linked dodecanoic acid'''<br />
'''Structure of E. coli FabF(K335A) mutant with covalently linked dodecanoic acid'''<br />


==Overview==
==Overview==
Bacterial infection remains a serious threat to human lives because of, emerging resistance to existing antibiotics. Although the scientific, community has avidly pursued the discovery of new antibiotics that, interact with new targets, these efforts have met with limited success, since the early 1960s. Here we report the discovery of platensimycin, a, previously unknown class of antibiotics produced by Streptomyces, platensis. Platensimycin demonstrates strong, broad-spectrum Gram-positive, antibacterial activity by selectively inhibiting cellular lipid, biosynthesis. We show that this anti-bacterial effect is exerted through, the selective targeting of beta-ketoacyl-(acyl-carrier-protein (ACP)), synthase I/II (FabF/B) in the synthetic pathway of fatty acids. Direct, binding assays show that platensimycin interacts specifically with the, acyl-enzyme intermediate of the target protein, and X-ray crystallographic, studies reveal that a specific conformational change that occurs on, acylation must take place before the inhibitor can bind. Treatment with, platensimycin eradicates Staphylococcus aureus infection in mice. Because, of its unique mode of action, platensimycin shows no cross-resistance to, other key antibiotic-resistant strains tested, including, methicillin-resistant S. aureus, vancomycin-intermediate S. aureus and, vancomycin-resistant enterococci. Platensimycin is the most potent, inhibitor reported for the FabF/B condensing enzymes, and is the only, inhibitor of these targets that shows broad-spectrum activity, in vivo, efficacy and no observed toxicity.
Bacterial infection remains a serious threat to human lives because of emerging resistance to existing antibiotics. Although the scientific community has avidly pursued the discovery of new antibiotics that interact with new targets, these efforts have met with limited success since the early 1960s. Here we report the discovery of platensimycin, a previously unknown class of antibiotics produced by Streptomyces platensis. Platensimycin demonstrates strong, broad-spectrum Gram-positive antibacterial activity by selectively inhibiting cellular lipid biosynthesis. We show that this anti-bacterial effect is exerted through the selective targeting of beta-ketoacyl-(acyl-carrier-protein (ACP)) synthase I/II (FabF/B) in the synthetic pathway of fatty acids. Direct binding assays show that platensimycin interacts specifically with the acyl-enzyme intermediate of the target protein, and X-ray crystallographic studies reveal that a specific conformational change that occurs on acylation must take place before the inhibitor can bind. Treatment with platensimycin eradicates Staphylococcus aureus infection in mice. Because of its unique mode of action, platensimycin shows no cross-resistance to other key antibiotic-resistant strains tested, including methicillin-resistant S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant enterococci. Platensimycin is the most potent inhibitor reported for the FabF/B condensing enzymes, and is the only inhibitor of these targets that shows broad-spectrum activity, in vivo efficacy and no observed toxicity.


==About this Structure==
==About this Structure==
2GFY is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli] with DAO as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Beta-ketoacyl-acyl-carrier-protein_synthase_I Beta-ketoacyl-acyl-carrier-protein synthase I], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.41 2.3.1.41] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2GFY OCA].  
2GFY is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli] with <scene name='pdbligand=DAO:'>DAO</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Beta-ketoacyl-acyl-carrier-protein_synthase_I Beta-ketoacyl-acyl-carrier-protein synthase I], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.41 2.3.1.41] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2GFY OCA].  


==Reference==
==Reference==
Line 15: Line 15:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Parthasarathy, G.]]
[[Category: Parthasarathy, G.]]
[[Category: Soisson, S.M.]]
[[Category: Soisson, S M.]]
[[Category: DAO]]
[[Category: DAO]]
[[Category: fabf; kasii; ketoacyl synthase]]
[[Category: fabf; kasii; ketoacyl synthase]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Wed Nov 21 11:10:55 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:31:18 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA